Table 2. Summary of outcomes in the studies.
| Trial | Median follow-up (months) | Median TTR (months) | Median DOR (months) | Median PFS (months) | Median OS (months) | PD-L1+Median TTR (months) | PD-L1+Median DOR (months) | PD-L1+Median PFS (months) | PD-L1+Median OS (months) |
|---|---|---|---|---|---|---|---|---|---|
| IMpassion130 | 12.9 | NR | 7.4 (95% CI, 6.9–9.0) | 7.2 (95% CI, 5.6–7.5) |
21.3 (95% CI, 17.3–23.4) | NR | 8.5 (95% CI, 7.3–9.7) | 7.5 (95% CI, 6.7–9.2) |
25 (95% CI, 22.6–not estimable) |
| GP28328 | 24.4 (95% CI, 22.1–28.8) |
NR | 9.1 (95% CI, 2.0–20.9) | 5.5 (95% CI, 5.1–7.7) |
14.7 (95% CI, 10.1–not estimable) | NR | 9.1 (95% CI, 2.9–16.2) | 6.9 (95% CI, 5.2–11.0) |
21.9 (95% CI, 13.1–not estimable) |
| JAVELIN | 10 (range, 6.0–15.2) |
2.7 (range, 1.3–4.1) |
Not estimable (95% CI, 6.7–not estimable) | 1.4 (95% CI, 1.4–1.4) |
8.1 (95% CI, 6.4–not estimable) | NR | NR | 1.4 months (95% CI, 1.3–1.4) |
6.5 (95% CI, 3.7–9.2) |
| PCD4989g | 25.3 (range, 0.4–45.6) |
NR | 21 (range, 3 to ≥38) | 1.4 (95% CI, 1.3–1.6) |
8.9 (95% CI, 7.0–12.6) | NR | NR | 1.4 (95% CI, 1.3–1.9) |
10.1 (95% CI, 7.0–13.8) |
| KEYNOTE-012 | 10.0 (range, 0.4–19.5) | 4.2 (range, 1.7–7.6) |
Not estimable (95% CI, 3.5 to ≥11.0) |
1.9 (95% CI, 1.7–5.5) |
11.2 (95% CI, 5.3–not estimable) | 4.2 (range, 1.7–7.6) |
Not estimable (95% CI, 3.5 to ≥11.0) | 1.9 months (95% CI, 1.7–5.5) |
11.2 (95% CI, 5.3–not estimable) |
| KEYNOTE-086 cohort A | 9.6 (range, 0.1–25.7) |
3.9 (range, 1.9–8.1) |
Not estimable (95% CI, ≥1.2 to ≥21.5) |
2.0 (95% CI, 1.9–2.0) |
9.0 (95% CI, 7.7–11.2) | 3.1 (range, 1.9–6.2) |
Not estimable (95% CI, 6.3 to ≥21.5) | 2.0 (95% CI, 1.9–2.1) |
8.8 (95% CI, 7.1–11.2) |
| KEYNOTE-086 cohort B | 12.3 (range, 0.9–23.5) |
2.0 (range, 1.7–6.2) |
10.4 (95% CI, 4.2 to ≥19.2) |
2.1 (95% CI, 2.0–2.2) |
18.0 (95% CI, 12.9–23.0) | 2.0 (range, 1.7–6.2) |
10.4 (95% CI, 4.2 to ≥19.2) | 2.1 (95% CI, 2.0–2.2) |
18.0 (95% CI, 12.9–23.0) |
| PANACEA | Phase Ib: 25.7 (IQR, 25.6–25.8); phase II: 13.6 (IQR, 11.6–18.4) | NR | NR | NR | NR | 2.7 (95% CI, 2.6–4.0) |
3.5 (95% CI, 2.7–not estimable) | 2.7 (95% CI, 2.6–4.0) |
Not estimable (95% CI, 13.1–not estimable) |
| KEYNOTE-028 | 9.7 (range, 0.7-31.8) | 1.7 (range, 1.7–1.9) |
12.0 (range, 7.4–15.9) | 1.8 (95% CI, 1.4–2.0) |
8.6 (95% CI, 7.3–11.6) | 1.7 (range, 1.7–1.9) |
12.0 (range, 7.4–15.9) | 1.8 (95% CI, 1.4–2.0) |
8.6 (95% CI, 7.3–11.6) |
TTR, time to response; DOR, duration of response; PFS, progression-free survival; OS, overall survival; 95% CI, 95% confidence interval; NR, not reported.